BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 16762733)

  • 1. Immunotherapy of melanoma.
    Rietschel P; Chapman PB
    Hematol Oncol Clin North Am; 2006 Jun; 20(3):751-66. PubMed ID: 16762733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for melanoma.
    Komenaka I; Hoerig H; Kaufman HL
    Clin Dermatol; 2004; 22(3):251-65. PubMed ID: 15262312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell-based immunotherapy of melanoma: what have we learned and how can we improve?
    Campoli M; Ferrone S
    Expert Rev Vaccines; 2004 Apr; 3(2):171-87. PubMed ID: 15056043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for metastatic melanoma.
    Zito CR; Kluger HM
    J Cell Biochem; 2012 Mar; 113(3):725-34. PubMed ID: 22006439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanoma cancer vaccines and anti-tumor T cell responses.
    Vujanovic L; Butterfield LH
    J Cell Biochem; 2007 Oct; 102(2):301-10. PubMed ID: 17647270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanoma and immunotherapy.
    Eggermont AM; Schadendorf D
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):547-64, ix-x. PubMed ID: 19464602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possibilities of immunotherapy and gene therapy for malignant melanoma.
    Crowley NJ; Seigler HF
    Semin Surg Oncol; 1993; 9(3):273-8. PubMed ID: 8516616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant immunotherapy for solid tumors: from promise to clinical application.
    Mocellin S; Rossi CR; Lise M; Marincola FM
    Cancer Immunol Immunother; 2002 Dec; 51(11-12):583-95. PubMed ID: 12439603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current immunotherapeutic strategies in malignant melanoma.
    Agostino NM; Ali A; Nair SG; Mosca PJ
    Surg Oncol Clin N Am; 2007 Oct; 16(4):945-73, xi. PubMed ID: 18022553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTLA-4 blockade: autoimmunity as treatment.
    Kapadia D; Fong L
    J Clin Oncol; 2005 Dec; 23(35):8926-8. PubMed ID: 16204008
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of immunotherapy in the treatment of melanoma.
    Faries MB
    Surg Oncol Clin N Am; 2006 Apr; 15(2):399-418. PubMed ID: 16632223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
    Berinstein NL
    Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
    Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
    Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells.
    Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M
    Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New therapeutic approachs in melanoma].
    Mortier L; Marchetti P; Gordower L; Charbonnier-Hatzfeld AS; Toungouz M; Velu T
    Rev Med Brux; 2004 Jun; 25(3):153-9. PubMed ID: 15291447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppression in melanoma immunotherapy: potential opportunities for intervention.
    Lizée G; Radvanyi LG; Overwijk WW; Hwu P
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2359s-2365s. PubMed ID: 16609059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for malignant melanoma--tracing Ariadne's thread through the labyrinth.
    Grange JM; Krone B; Stanford JL
    Eur J Cancer; 2009 Sep; 45(13):2266-73. PubMed ID: 19497734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.